ArticleInfection and drug resistance2020
A Multidrug-resistant Monophasic
Article in Infection and drug resistance, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 15 citations in OpenAlex.
- Antimicrobial ResistantPathogens (Basel, Switzerland) · 2025Review
- Prevalence, antimicrobial resistance and phylogenetic analysis ofVeterinary and animal science · 2025Article
- Prevalence and Characteristics of Plasmid-Mediated Fosfomycin Resistance GenePathogens (Basel, Switzerland) · 2024Article
- Fosfomycin resistance mechanisms inFrontiers in cellular and infection microbiology · 2023Review
- Article
- Characterization of NDM-5-producingZoological research · 2022Article
- Epidemiology ofFrontiers in microbiology · 2022Article
- Emergence of IncHI2 Plasmid-Harboring blaNDM-5 from PorcinePathogens (Basel, Switzerland) · 2021Article
- Recent Advances in the Detection of Antibiotic and Multi-Drug ResistantInternational journal of molecular sciences · 2021Review
- The Rising Burden of Salmonellosis Caused by MonophasicAntibiotics (Basel, Switzerland) · 2021Article
- Genetic Characterization ofFrontiers in microbiology · 2021Article
- Occurrence ofInfection and drug resistance · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPolymyxins are currently regarded as a possible last-resort therapy to eradicate multidrug-resistant (MDR) gram-negative bacteria. Meanwhile, the old antimicrobial agent fosfomycin has recently been reintroduced into clinical use for the treatment of extended-spectrum β-lactamase (ESBL)-producing and carbapenem-resistant
methodsA
results
conclusionThis study reported a the multidrug-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.